InvestBio News

⬇ continuation ⬇

Valion Bio (NASDAQ: $VBIO) formulated a needle-free oral mucosal delivery for Entolimod using Shear Kershman Laboratories’ BioViscid tech, creating a second clinical path alongside injectable Entolimod for acute radiation syndrome. A study will evaluate bioavailability. While it could expand radiation countermeasures with easier dosing, clinical efficacy, approval, and government contracts are unconfirmed.


#VBIO

📰 Pre-Market Biotech Stock
〰〰〰〰〰〰〰〰〰〰〰〰

Foghorn Therapeutics (NASDAQ: $FHTX) and Eli Lilly (NASDAQ: $LLY) terminated clinical development of FHD-909 after a Phase 1 dose-escalation evaluation. The decision concludes their partnership around the selective SMARCA2 degrader, allowing Foghorn to reallocate operational focus toward its internal drug pipeline.

Filana Therapeutics (NASDAQ: $FLNA) Chief Executive Officer Richard Barry purchased 93,091 common shares in the open market for approximately $78,196 at $0.84 per share, increasing his indirect holdings through a trust to 1.03 million shares and signaling insider support.

Unicycive Therapeutics (NASDAQ: $UNCY) saw its price target lowered from $15 to $13 by H.C. Wainwright. Separately, the firm named Meredith Manning, ex-Chief Commercial Officer at Soleno Therapeutics, to its board of directors and as chair of the nominating and corporate governance committee, bringing launch expertise following Soleno’s takeover by Neurocrine.

Monte Rosa Therapeutics (NASDAQ: $GLUE) announced positive Phase 1 GFORCE-1 trial results evaluating MRT-8102. The candidate achieved 80%–90% NEK7 degradation and broad reductions across inflammatory, thrombogenic, and lipid-related biomarkers in participants with elevated cardiovascular risk. MRT-8102 demonstrated a favorable safety profile with no serious adverse events. Monte Rosa intends to initiate multiple Phase 2 trials, targeting coronary artery disease in 1H 2027, gout in Q4 2026/Q1 2027, and hidradenitis suppurativa in 1H 2027 to broaden its NLRP3-driven pipeline.

Liquidia Corporation (NASDAQ: $LQDA) faced an unfavorable district court decision regarding its YUTREPIA patent litigation. The court upheld two '327 patent claims related to treating pulmonary hypertension associated with interstitial lung disease as valid and infringed, while striking down four additional claims. Liquidia intends to contest the judgment and excise the pulmonary hypertension associated with interstitial lung disease indication from YUTREPIA's prescribing information. Potential judicial remedies span from targeted labeling revisions to full market limitations, introducing significant legal and commercial headwinds.

Allarity Therapeutics (NASDAQ: $ALLR) updated on patent and lab progress for its stenoparib Drug Response predictor patient-selection platform. The update highlighted new IP for market exclusivity and CLIA-certified internal testing. Previous Phase 2 ovarian cancer data linked high stenoparib-DRP scores to improved overall survival, supporting the assay's use for pivotal trial enrollment and partnership opportunities.

AEON Biopharma (NYSE: $AEON) provided updates following Type 2b feedback from the FDA regarding a streamlined regulatory pathway for its BOTOX biosimilar candidate, ABP-450. Scientific bridging will permit previous comparative clinical work to serve as supportive data. AEON intends to submit an Investigational New Drug application during Q4 2026 to start a CMAP pharmacodynamic study in Q1 2027, leveraging analytical, PD, and historical clinical results throughout 2027 to potentially bypass a dedicated comparative efficacy trial.

NewGenIvf Group (NASDAQ: $NIVF) completed a $1.25 million public offering comprising 125,000 Class A common shares alongside pre-funded warrants for up to 17.73 million shares at an effective price of $0.07 apiece. Net capital is designated for working capital needs, debt restructuring, Nodexus cell-sorting integration, and an investment in K25.ai, though the large pre-funded warrant component poses notable dilution risk.


#AEON #ALLR #FHTX #FLNA #GLUE #LLY #LQDA #NIVF #UNCY

💊 Pipeline updates
〰〰〰〰〰〰〰〰〰〰〰

Company: $VNDA - Vanda Pharmaceuticals Inc.

Drug: HETLIOZ (tasimelteon) (Delayed sleep phase disorder (DSPD))

Stage: Phase 3

Catalyst: Phase 3 data study met its primary endpoint, noted September 30, 2026.

〰〰〰〰〰〰〰〰〰〰〰

Company: $CYTH - Cyclo Therapeutics Inc.,

Drug: RFL - Rafael Holdings Inc. Class B (Trappsol Cyclo - (TransportNPC))

Stage: New Drug Application Filing

Catalyst: Phase 3 study did not meet its primary endpoint, noted September 30, 2026. New Drug Application submission expected in 4Q 2026

〰〰〰〰〰〰〰〰〰〰〰

Company: $GANX - Gain Therapeutics Inc.

Drug: rexaceract (GT-02287) (GBA1 and Idiopathic Parkinson's Disease)

Stage: Phase 2

Catalyst: Phase 1/2 long-term open-label data to be presented at myelodysplastic syndromes on October 7, 2026.

〰〰〰〰〰〰〰〰〰〰〰

Company: $DBVT - DBV Technologies S.A.

Drug: Viaskin Peanut - (VITESSE) (Peanut allergy)

Stage: BLA Filing

Catalyst: BLA submitted to the FDA, noted September 30, 2026.

〰〰〰〰〰〰〰〰〰〰〰

Company: $ABVX - Abivax SA

Drug: Obefazimod - (ABTECT) (Ulcerative colitis)

Stage: Phase 3

Catalyst: Phase 3 study to present maintenance data at UEG Week on October 19, 2026. Pre-NDA interaction with the FDA concluded that the company remains on track to submit the New Drug Application by the end of 2026. Phase 3 part 2 data reported 37.2% of induction non-responders achieving clinical remission and 34.5% achieving endoscopic remission at Week 44 following continued 50 mg treatment, June 29, 2026.

〰〰〰〰〰〰〰〰〰〰〰

Company: $RFL - Rafael Holdings Inc. Class B,

Drug: ERNA - Ernexa Therapeutics Inc. (ERNA-101)

Stage: IND-Enabling

Catalyst: Investigational New Drug submission planned 4Q 2026. Phase 1 planned for 4Q 2026. Independent contract research organization reproduced larger preclinical study with success, which reinforces Investigational New Drug advancement confidence, noted July 15, 2026. Preclinical data showed that ERNA-101 achieved 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models, noted May 6, 2026.

〰〰〰〰〰〰〰〰〰〰〰

Company: $JBIO - Jade Biosciences Inc.

Drug: JADE301 (Muscle and skin manifestations)

Stage: Phase 1

Catalyst: Preclinical study demonstrated high-affinity, selective IFN-β binding and greater functional potency than a dazukibart comparator in disease-relevant human cells, noted September 30, 2026. Phase 1 healthy volunteer trial expected to begin in the 4Q 2026; interim data anticipated in 2H 2027.

〰〰〰〰〰〰〰〰〰〰〰

Company: $CNTB - Connect Biopharma Holdings Limited

Drug: Rademikibart - (Seabreeze STAT COPD) (Chronic obstructive pulmonary disease)

Stage: Phase 2

Catalyst: Phase 2 study met its primary endpoint, as noted on September 30, 2026. The study showed favorable tolerability, supporting planned FDA engagement on a Phase 3 program.

〰〰〰〰〰〰〰〰〰〰〰

Company: $LLY - Eli Lilly and Company

Drug: EBGLYSS (lebrikizumab-lbkz) - (ADtouch) (Moderate-to-severe hand and foot atopic dermatitis)

Stage: Phase 3

Catalyst: Phase 3b monotherapy met its primary endpoint with more than half of patients achieving clear or almost clear skin on their hands and feet (HF-IGA 0/1) by Week 16, with significant skin clearance as early as one month, noted September 30, 2026.

〰〰〰〰〰〰〰〰〰〰〰

Company: $Immune-mediated necrotizing myopathy - Immunome Inc.

Drug: IM-1340 (Advanced solid tumors)

Stage: Phase 1

Catalyst: Phase 1 planned for 4Q 2026. Investigational New Drug cleared by the FDA, noted September 30, 2026.

〰〰〰〰〰〰〰〰〰〰〰

#ABVX #CNTB #CYTH #DBVT #GANX #Immune #JBIO #LLY #RFL #VNDA

⬇ continuation ⬇

Rafael Holdings (NYSE: $RFL) reported Phase 3 TransportNPC study results for Trappsol Cyclo in Niemann-Pick disease type C. While the trial missed statistical significance on the primary 4DNPCSS endpoint, Trappsol Cyclo slowed disease progression by 64% versus placebo. In a prespecified subgroup of patients on concurrent miglustat and/or leucine (83% of subjects), it demonstrated a statistically significant 71% reduction in progression with a safety profile consistent with prior data. The company still plans to submit an New Drug Application in Q4 2026. Shares closed down 35% at $1.32.

Contineum Therapeutics (NASDAQ: $CTNM) saw its Buy recommendation and $24 price goal reaffirmed by Jones Research following a rival update highlighting hepatic toxicity risks in Bristol Myers’ Phase 3 admilparant extension trial. Analysts suggest this blinded safety finding could give PIPE-791 a competitive edge if it maintains a cleaner hepatic tolerability profile. Shares closed up 17% at $13.42.

Tenon Medical (NASDAQ: $TNON) initiated the full commercial rollout of its 3D-printed titanium lateral screw for the SImmetry+ Sacroiliac Joint Fusion System. The commercial expansion follows an initial Alpha release that yielded roughly $1.2 million in added revenue between late Q4 2025 and Q3 2026, backing broader market deployment and inventory scaling to satisfy projected demand. Shares closed up 50% at $4.09.


#CTNM #RFL #TNON

📰 Daily Biotech Stock Updates
〰〰〰〰〰〰〰〰〰〰〰〰

Connect Biopharma (NASDAQ: $CNTB) shares closed up 11% at $1.1 announced positive topline Phase 2 Seabreeze STAT chronic obstructive pulmonary disease results evaluating single-dose rademikibart in acute chronic obstructive pulmonary disease exacerbations accompanied by type 2 inflammation. Compared to placebo, the treatment demonstrated an 81% reduction in treatment failure at Week 4, an 85% decline in new moderate-to-severe exacerbations, and a 100% decrease in new hospitalizations or emergency department visits. The therapy was favorably tolerated, providing strong support for upcoming FDA discussions regarding a Phase 3 development program.

NuCana (NASDAQ: $NCNA) was granted a European composition-of-matter patent covering NUC-7738, bolstering intellectual property rights for its lead Phase 1/2 cancer asset currently in combination testing alongside pembrolizumab for PD-1-refractory metastatic melanoma. Broadening a portfolio exceeding 85 global granted patents, the grant solidifies commercial exclusivity for NUC-7738 in key regions, while current capital reserves support operational runway through 2029. Shares closed up 12% at $1.35.

Tiziana Life Sciences (NASDAQ: $TLSA) filed an application with the FDA seeking Orphan Drug Designation for intranasal foralumab to treat multiple system atrophy, a sparse neurodegenerative disorder lacking approved disease-modifying options. Currently under assessment in an open-label Phase 2a trial measuring microglial activation, safety, and clinical endpoints, the candidate could secure seven years of commercial exclusivity in the U.S. market should approval be granted. Shares closed up 16% at $1.11.

Liquidia (NASDAQ: $LQDA) disclosed an unfavorable district court decision regarding Hatch-Waxman litigation for YUTREPIA. The court validated and found infringement on two asserted '327 patent claims while invalidating others. The company intends to appeal and strip the pulmonary hypertension associated with interstitial lung disease indication from YUTREPIA's label. Meanwhile, judicial consideration of potential remedies—spanning narrower labeling to broader marketing restrictions—presents significant ongoing legal and commercial headwinds. Shares closed down 57% at $30.26.

Silexion Therapeutics (NASDAQ: $SLXN) administered the initial dose in its international Phase 2/3 study evaluating SIL204 in locally advanced pancreatic cancer, advancing the primary KRAS-directed RNAi candidate into clinical evaluation. The protocol pairs intratumoral and subcutaneous SIL204 alongside standard chemotherapy, initiating with an 18-subject safety run-in ahead of enrolling roughly 166 randomized patients across sites in Israel and Germany. Shares closed down 13% at $0.28.

Pyxis Oncology (NASDAQ: $PYXS) announced the pricing of a public offering to generate roughly $110 million in upfront proceeds via common stock, pre-funded warrants, and accompanying warrants, with potential gross proceeds reaching up to $172.6 million if all warrants are fully exercised. The capital injection is slated to advance primary candidate MICVO past critical developmental hurdles, such as the intended Phase 3 Headliner trial in 2L+ recurrent or metastatic head and neck cancer. However, the attached warrant structure introduces significant prospective equity dilution, linked partly to the expected overall survival readout in the first half of 2027. Shares closed down 20% at $2.33.


#CNTB #LQDA #NCNA #PYXS #SLXN #TLSA

📰 Pre-Market Biotech Stock
〰〰〰〰〰〰〰〰〰〰〰〰

Connect Biopharma (NASDAQ: $CNTB) reported positive Phase 2 Seabreeze STAT chronic obstructive pulmonary disease topline data for single-dose rademikibart in acute chronic obstructive pulmonary disease exacerbations with type 2 inflammation, showing 81% lower Week 4 treatment failure, 85% lower new moderate-to-severe exacerbations, and 100% reduction in new ED visits or hospitalizations versus placebo, with favorable tolerability supporting planned FDA engagement on a Phase 3 program.

Ernexa Therapeutics (NASDAQ: $ERNA) announced upcoming preclinical presentations at the 2026 Cell & Gene Meeting on the Mesa evaluating ERNA-101 and its iMSC platform. Results demonstrated total tumor elimination when paired with PD-1 inhibition in ovarian cancer models. The company expects to submit an Investigational New Drug in 2026 to evaluate the candidate in platinum-resistant ovarian cancer ahead of potential trials across additional solid tumors.

Sagimet Biosciences (NASDAQ: $SGMT) revealed favorable 52-week Phase 3 open-label extension trial results via partner Ascletis for denifanstat in Chinese acne patients, demonstrating a 56.7% Investigator's Global Assessment success rate alongside a 71.8% drop in overall lesions and a 76.9% decrease in inflammatory lesions without any permanent treatment cessations from adverse events, laying groundwork for launching U.S. Phase 3 AURORA trial screening during October 2026.

Rafael Holdings (NYSE: $RFL) reported Phase 3 TransportNPC study results for Trappsol Cyclo in Niemann-Pick disease type C. While the trial missed statistical significance on the primary 4DNPCSS endpoint, Trappsol Cyclo slowed disease progression by 64% versus placebo. In a prespecified subgroup of patients on concurrent miglustat and/or leucine (83% of subjects), it demonstrated a statistically significant 71% reduction in progression with a safety profile consistent with prior data. The company still plans to submit an New Drug Application in Q4 2026.

Silexion Therapeutics (NASDAQ: $SLXN) closed a warrant exercise transaction generating roughly $837,000 in gross proceeds via 3.22 million warrants adjusted to an exercise price of $0.2603, directing capital toward working capital needs. Participating holders received 6.43 million replacement warrants at $0.2603, while outstanding Series E warrants were similarly repriced to $0.2603, expanding long-term dilution potential.

DBV Technologies (NASDAQ: $DBVT) submitted a BLA to the FDA seeking approval of VIASKIN Peanut for children aged 4 to 7 years with peanut allergies, leveraging findings from the 654-subject Phase 3 VITESSE study. The company requested Priority Review for its epicutaneous patch, which holds Breakthrough Therapy status, advancing the regulatory timeline for its non-oral immunotherapy platform.

Pyxis Oncology (NASDAQ: $PYXS) priced a public offering expected to raise approximately $110 million upfront through common stock, pre-funded warrants and accompanying warrants, with up to an additional $172.6 million if all warrants are exercised. Proceeds will fund lead asset MICVO through key milestones, including the planned Phase 3 Headliner trial in 2L+ recurrent/metastatic head and neck cancer, while the warrant structure creates substantial future dilution potential tied in part to the anticipated 1H 2027 overall survival readout.


#CNTB #DBVT #ERNA #PYXS #RFL #SGMT #SLXN

⬇ continuation ⬇

Company: $ARGX - argenx SE

Drug: Empasiprubart (ARGX-117) - (EMPASSION) (Multifocal motor neuropathy)

Stage: Phase 3

Catalyst: Phase 2 trial results to be presented at American Association of Neuromuscular and Electrodiagnostic Medicine on September 29–October 2, 2026. Registrational trial topline data results due in 4Q 2026.

〰〰〰〰〰〰〰〰〰〰〰

Company: $VSTM - Verastem Inc.

Drug: Avutometinib in Combination with Defactinib - (RAMP 201) (Low-Grade Serous Ovarian Cancer)

Stage: Phase 2

Catalyst: Phase 2 published a two-year follow-up in recurrent Low-grade serous ovarian cancer, showing avutometinib plus defactinib maintained durable activity with a 31.1-month median duration of response, a 12.9-month median progression-free survival, and no new safety signals across KRAS-mutated and wild-type patients, reinforcing the dataset that supported FDA Accelerated Approval in KRAS-mutated recurrent Low-grade serous ovarian cancer after prior systemic therapy, noted September 29, 2026.

〰〰〰〰〰〰〰〰〰〰〰

Company: $NTHI - NeOnc Technologies Holdings Inc.

Drug: NEO212 (Newly diagnosed gliomas, recurrent Glioblastoma multiforme and brain metastases)

Stage: Phase 2a

Catalyst: Type B EoP1 meeting scheduled for November 17, 2026. End-of-Phase 1 Type B with FDA scheduled November 17, 2026 to discuss Phase 2 trial design, endpoints, and recommended Phase 2 dose (610 mg) for NEO212 in central nervous system cancers, noted September 28, 2026.

〰〰〰〰〰〰〰〰〰〰〰

Company: $VOR - Vor Biopharma Inc.

Drug: Telitacicept - (UPSTREAM MG) (Generalized Myasthenia Gravis)

Stage: Phase 3

Catalyst: Phase 3 post hoc analysis presented at the American Association of Neuromuscular and Electrodiagnostic Medicine from Chinese collaborator RemeGen Co showed that more than 94% of participants achieved a ≥5-point Myasthenia Gravis Activities of Daily Living improvement at Week 48, noted September 29, 2026. Phase 3 enrollment completed, noted September 8, 2026.

〰〰〰〰〰〰〰〰〰〰〰

Company: $TECX - Tectonic Therapeutic Inc.

Drug: TX2100 (Healthy volunteers)

Stage: Phase 1a

Catalyst: Phase 1a topline demonstrated that single ascending doses of TX2100 were generally safe and well-tolerated in healthy adult volunteers, the FDA granted fast-track designation, noted September 29, 2026. Phase 1b open-label extension study planned by year end 2026 and Phase 2 planned in Early 2027.

〰〰〰〰〰〰〰〰〰〰〰

#ARGX #NTHI #TECX #VOR #VSTM

💊 Pipeline updates
〰〰〰〰〰〰〰〰〰〰〰

Company: $ACXP - Acurx Pharmaceuticals Inc.

Drug: Ibezapolstat - (ASPIRE) (C. difficile Infection)

Stage: Phase 2

Catalyst: Phase 2 MaGic open-label extension data in Generalized Myasthenia Gravis presented at American Association of Neuromuscular and Electrodiagnostic Medicine / MGFA Scientific Session on September 29–October 2, 2026; showed sustained safety and efficacy, noted September 29, 2026. Phase 3 Type C Meeting indicated openness to a New Drug Application submission supported by a single Phase 3 trial, noted August 3, 2026. Phase 3 trial ready.

〰〰〰〰〰〰〰〰〰〰〰

Company: $DYN - Dyne Therapeutics Inc.

Drug: Zeleciment basivarsen (z-basivarsen) (DYNE-101) - (ACHIEVE) (Myotonic Dystrophy Type 1)

Stage: Phase 1/2

Catalyst: Additional Phase 1/2 data to be shared at WMS showed functional improvement versus baseline, versus placebo and versus a matched natural history cohort across multiple measures at 12 months, noted September 29, 2026. The fully enrolled registrational expansion cohort remains on track for 1Q 2027 topline data to support a potential 3Q 2027 BLA AA submission.

〰〰〰〰〰〰〰〰〰〰〰

Company: $ALDX - Aldeyra Therapeutics Inc.

Drug: Reproxalap (ADX-102) - (CHAMBER) (Dry Eye Disease)

Stage: complete response letter

Catalyst: Aldeyra intends to submit a Formal Dispute Resolution Request (FDRR) to the FDA for reproxalap. The FDRR, which is expected to be reviewed by the FDA’s Office of New Drugs (OND) is designed to appeal the March 16, 2026 complete response letter. Submission of the FDRR and a meeting with the OND are expected in 4Q 2026, noted September 29, 2026. complete response letter issued by the FDA on March 17, 2026.

〰〰〰〰〰〰〰〰〰〰〰

Company: $MBRX - Moleculin Biotech Inc.

Drug: Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE) (Acute Myeloid Leukemia)

Stage: Phase 2/3

Catalyst: Phase 2/3 Part A enrollment completed, noted September 29, 2026. With enrollment completed, the trial is on track for a comprehensive 1Q 2027 readout.

〰〰〰〰〰〰〰〰〰〰〰

Company: $CRBP - Corbus Pharmaceuticals Holdings Inc.

Drug: CRB-701 (SYS6002) - (TEMPO-1) (Oropharyngeal squamous cell carcinoma)

Stage: Phase 1/2

Catalyst: Phase 2 study dosing commenced, noted September 29, 2026. FDA cleared the start of the registrational study, noted July 28, 2026. Phase 1/2 registrational study enrollment planned for September 2026. Phase 1/2 updated monotherapy data expected at Key Opinion Leader during American Society of Clinical Oncology with data confirming an ORR of 42.9% observed in 2L oropharyngeal squamous cell carcinoma at 3.6 mg/kg with median DOR of 6.3 months and progression-free survival of 5.6 months (ongoing), noted June 1, 2026.

〰〰〰〰〰〰〰〰〰〰〰

Company: $NAMS - NewAmsterdam Pharma Company N.V.

Drug: Obicetrapib - (OCEAN) (Alzheimer's Disease)

Stage: Phase 2

Catalyst: Phase 2 trial results to be presented at American Association of Neuromuscular and Electrodiagnostic Medicine on September 29–October 2, 2026. New trial planned for 2026. Phase 2a data observed reductions of 11% and 12% in 24- and 27-hydroxycholesterol in cerebrospinal fluid, respectively, indicating potential improvement of cholesterol metabolism in the brain. Observed 8% increase in Aβ42/40 ratio, a key biomarker of AD risk, suggesting improvement in disease pathology, noted September 21, 2023. Additional data shared at EAS on May 27, 2024.

〰〰〰〰〰〰〰〰〰〰〰

#ACXP #ALDX #CRBP #DYN #MBRX #NAMS

⬇ continuation ⬇

uniQure (NASDAQ: $QURE) reported updated Phase 1/2 data for ifezuntirgene inilparvovec in Huntington’s disease, demonstrating dose-dependent slowing of disease progression. At 48 months, high-dose participants (n=12) showed a 44% deceleration on composite Unified Huntington's Disease Rating Scale and a 61% reduction on TFC (nominally significant). 36-month data (n=15) showed enhanced efficacy, supporting the confirmatory trial protocol and BLA submission. Shares closed down 37% at $24.51.


#QURE

📰 Daily Biotech Stock Updates
〰〰〰〰〰〰〰〰〰〰〰〰

Iovance Biotherapeutics (NASDAQ: $IOVA) increased its 2026 revenue forecast to $410–$420 million—marking an approximate 15% midpoint surge and nearly 60% year-over-year growth—driven by record Q2 revenues of $99.3 million, strong domestic uptake of Amtagvi and Proleukin, and the expansion of its authorized treatment site network to at least 110 locations by the end of the year. Shares closed up 31% at $14.45.

Silexion Therapeutics (NASDAQ: $SLXN) announced agreements for the immediate exercise of 3.22 million existing warrants at a reduced price of $0.2603 per share, yielding roughly $837,000 in gross proceeds for working capital needs, while issuing 6.43 million replacement warrants at the identical price and lowering outstanding Series E warrants to $0.2603, driving notable equity dilution potential. Shares closed up 28% at $0.32.

Aldeyra Therapeutics (NASDAQ: $ALDX) announced plans to submit a Formal Dispute Resolution Request in Q4 2026 to appeal the FDA's third Complete Response Letter for reproxalap in dry eye disease, which cited insufficient efficacy data. Seeking to resolve the issue without new studies, the company expects an Office of New Drugs conference in Q4 2026 and extended its operational runway into 2029 with $45.1 million in liquid assets as of June 30, 2026. Shares closed up 14% at $1.32.

Ginkgo Bioworks (NYSE: $DNA) co-founded the Antibody Developability Consortium with Apheris and AbbVie, argenx, Lundbeck, and Takeda to build a 10,000-antibody dataset and train artificial intelligence models for manufacturing risk assessment. Ginkgo leads characterization and model training, Apheris secures data governance, and an initial dataset release is planned for early 2027. Shares closed up 14% at $11.96.

Cosmos Health (NASDAQ: $COSM) announced record Q2 2026 revenue topped $15 million at its fully owned CosmoFarm unit—reflecting a $60 million annualized run rate alongside 4.3x expansion post-acquisition—while robotics, automation, and artificial intelligence integration position operations to accommodate over $100 million in annual top-line capacity and a network of 1,500+ pharmacies bolsters operational efficiency toward its $200.6 million revenue target for 2029. Shares closed up 14% at $0.42.

CDT Equity (NASDAQ: $CDT) showcased recent patent applications for quantum computing technology via portfolio company Sarborg, leveraging quantum sampling within drug discovery and disease biology spanning 150 disease networks. CDT’s 22.7% equity position reflects an estimated valuation of $161 million following Sarborg’s recent funding round, which valued the private venture at around $709 million on a fully diluted basis, while Sarborg actively pursues a strategic collaboration alongside a top quantum computing firm to further scale its technology. Shares closed down 24% at $1.45.

BeyondSpring (NASDAQ: $BYSI) gained FDA Fast Track designation for plinabulin with docetaxel in prior chemoimmunotherapy-treated non-squamous non-small-cell lung cancer lacking actionable genomic mutations. BeyondSpring also sold a controlling stake in its Chinese subsidiary to help finance the Phase 3 DUBLIN-4 study, funding about half of its 442 target participants and lowering capital needs before the 221-event progression-free survival interim analysis. Shares closed down 31% at $0.77.


#ALDX #BYSI #CDT #COSM #DNA #IOVA #SLXN